Literature DB >> 30615852

Generation and characterization of antagonistic anti-human interleukin (IL)-18 monoclonal antibodies with high affinity: Two types of monoclonal antibodies against full-length IL-18 and the neoepitope of inflammatory caspase-cleaved active IL-18.

Yuko Nariai1, Hiroki Kamino1, Eiji Obayashi1, Hiroaki Kato1, Gyosuke Sakashita1, Tomoko Sugiura1, Kiyoshi Migita2, Tomohiro Koga3, Atsushi Kawakami3, Kazuma Sakamoto4, Kenji Kadomatsu4, Makoto Nakakido5, Kouhei Tsumoto6, Takeshi Urano7.   

Abstract

Interleukin-18 (IL-18) is a pro-inflammatory cytokine that evokes both innate and acquired immune responses. IL-18 is initially synthesized as an inactive precursor and the cleavage for processing into a mature, active molecule is mediated by pro-inflammatory caspases following the activation of inflammasomes. Two types of monoclonal antibodies were raised: anti-IL-1863-68 antibodies which recognize full-length1-193 and cleaved IL-18; and anti-IL-18 neoepitope antibodies which specifically recognize the new N-terminal 37YFGKLESK44 of IL-18 cleaved by pro-inflammatory caspase-1/4. These mAbs were suitable for Western blotting, capillary Western immunoassay (WES), immunofluorescence, immunoprecipitation, and function-blocking assays. WES analysis of these mAbs allowed visualization of the IL-18 bands and provided a molecular weight corresponding to the pro-inflammatory caspase-1/4 cleaved, active form IL-1837-193, and not to the inactive precursor IL-18, in the serum of patients with adult-onset Still's disease (6/14, 42%) and hemophagocytic activation syndrome (2/6, 33%). These monoclonal antibodies will be very useful in IL-18 and inflammasome biology and for diagnostic and therapeutic strategies for inflammatory diseases.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 30615852     DOI: 10.1016/j.abb.2019.01.001

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  6 in total

1.  Clinical characteristics and comorbidities in adult-onset Still's disease using a large US administrative claims database.

Authors:  Aleksander Lenert; GYeon Oh; Michael J Ombrello; Sujin Kim
Journal:  Rheumatology (Oxford)       Date:  2020-07-01       Impact factor: 7.580

2.  Exploring Molecular Mechanisms Involved in the Development of the Depression-Like Phenotype in Interleukin-18-Deficient Mice.

Authors:  Kyosuke Yamanishi; Masahiro Miyauchi; Keiichiro Mukai; Takuya Hashimoto; Noriko Uwa; Hitomi Seino; Wen Li; Naomi Gamachi; Masaki Hata; Sachi Kuwahara-Otani; Seishi Maeda; Yuko Watanabe; Hiromichi Yamanishi; Hideshi Yagi; Haruki Okamura; Hisato Matsunaga
Journal:  Biomed Res Int       Date:  2021-10-18       Impact factor: 3.411

3.  Hypoxia-inducible factor (HIF)-1α-induced regulation of lung injury in pulmonary aspiration is mediated through NF-kB.

Authors:  Madathilparambil V Suresh; George Yalamanchili; Tejeshwar C Rao; Sinan Aktay; Alex Kralovich; Yatrik M Shah; Krishnan Raghavendran
Journal:  FASEB Bioadv       Date:  2022-01-12

Review 4.  Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: Biological role in induction, regulation, and treatment.

Authors:  Stella Amarachi Ihim; Sharafudeen Dahiru Abubakar; Zeineb Zian; Takanori Sasaki; Mohammad Saffarioun; Shayan Maleknia; Gholamreza Azizi
Journal:  Front Immunol       Date:  2022-08-11       Impact factor: 8.786

5.  Beneficial Effects of Sagacious Confucius' Pillow Elixir on Cognitive Function in Senescence-Accelerated P8 Mice (SAMP8) via the NLRP3/Caspase-1 Pathway.

Authors:  Zhitao Hou; Fengjin Li; Jing Chen; Yitian Liu; Changyuan He; Meng Wang; Tingting Mei; Yue Zhang; Liying Song; Xianming Shao
Journal:  Evid Based Complement Alternat Med       Date:  2019-11-06       Impact factor: 2.629

Review 6.  Human Autoinflammatory Diseases Mediated by NLRP3-, Pyrin-, NLRP1-, and NLRC4-Inflammasome Dysregulation Updates on Diagnosis, Treatment, and the Respective Roles of IL-1 and IL-18.

Authors:  Sara Alehashemi; Raphaela Goldbach-Mansky
Journal:  Front Immunol       Date:  2020-08-25       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.